14.02.2025

PULMONARY FUNCTION TESTS

DR SHAGUN BATRA JUNIOR RESIDENT DEPARTMENT OF INTERNAL MEDICINE

"The interpretation of PFTs should focus on values of airflow, lung volume and gas transfer measurements to recognize patterns of altered physiology. PFTs alone should not be used to diagnose a specific pathological condition."

WHY DO WE NEED THEM?

DIAGNOSIS

• SEVERITY ASSESSMENT AND PROGNOSTICATION

FOLLOW UP AND MONITORING

• PRE-OPERATIVE EVALUATION

TESTS IN THE DOMAIN

Respiratory function	Parameters	Tests
Ventilation	Flow	 Spirometry (post bronchodilator, FV loop, BCT, supine and sitting)
	Volume	 Gas dilution methods Body plethysmography Radiographic methods
	Elastic recoil	Impulse oscillometryForced oscillation methods
Diffusion	Transfer factor	- DLCO
Others	Exercise	 6 minute walk test Incremental shuttle walk test Endurance shuttle walk test CPET
	Oxygenation	Pulse oximetryABG

AMERICAN THORACIC SOCIETY DOCUMENTS

Standardization of Spirometry 2019 Update

An Official American Thoracic Society and European Respiratory Society Technical Statement

Brian L. Graham, Irene Steenbruggen, Martin R. Miller, Igor Z. Barjaktarevic, Brendan G. Cooper, Graham L. Hall, Teal S. Hallstrand, David A. Kaminsky, Kevin McCarthy, Meredith C. McCormack, Cristine E. Oropez, Margaret Rosenfeld, Sanja Stanojevic, Maureen P. Swanney[†], and Bruce R. Thompson; on behalf of the American Thoracic Society and the European Respiratory Society

THIS OFFICIAL TECHNICAL STATEMENT WAS APPROVED BY THE AMERICAN THORACIC SOCIETY AND THE EUROPEAN RESPIRATORY SOCIETY SEPTEMBER 2019



There are 3 key elements to obtain high quality pulmonary function data:

Accurate and precise instrumentation

A patient/subject capable of performing acceptable and repeatable measurements A motivated technologist to elicit maximum performance from the patient

Ruppel GL, Enright PL. Pulmonary function testing. Respir Care 2012; 57:165–175.

WHEN TO DO AND WHEN NOT TO DO?

Table 1. Indications for Spirometry

D	iag	no	s	s
	_			

- To evaluate symptoms, signs, or abnormal laboratory test results To measure the physiologic effect of disease or disorder To screen individuals at risk of having pulmonary disease
- To assess preoperative risk
- To assess prognosis

Monitoring

- To assess response to therapeutic intervention
- To monitor disease progression
- To monitor patients for exacerbations of disease and recovery from exacerbations
- To monitor people for adverse effects of exposure to injurious agents
- To watch for adverse reactions to drugs with known pulmonary toxicity

Disability/impairment evaluations

- To assess patients as part of a rehabilitation program
- To assess risks as part of an insurance evaluation
- To assess individuals for legal reasons

Other

- Research and clinical trials
- Epidemiological surveys
- Derivation of reference equations
- Preemployment and lung health monitoring for at-risk occupations
- To assess health status before beginning at-risk physical activities

Table 2. Relative Contraindications for Spirometry

Due to increases in myocardial demand or changes in blood pressure Acute myocardial infarction within 1 wk Systemic hypotension or severe hypertension Significant atrial/ventricular arrhythmia Noncompensated heart failure Uncontrolled pulmonary hypertension Acute cor pulmonale Clinically unstable pulmonary embolism History of syncope related to forced expiration/cough

- Due to increases in intracranial/intraocular pressure Cerebral aneurysm Brain surgery within 4 wk Recent concussion with continuing symptoms Eye surgery within 1 wk
- Due to increases in sinus and middle ear pressures Sinus surgery or middle ear surgery or infection within 1 wk
- Due to increases in intrathoracic and intraabdominal pressure Presence of pneumothorax Thoracic surgery within 4 wk Abdominal surgery within 4 wk Late-term pregnancy

Infection control issues

Active or suspected transmissible respiratory or systemic infection, including tuberculosis Physical conditions predisposing to transmission of infections, such as hemoptysis, significant secretions, or oral lesions or oral bleeding Diagnosis

To evaluate symptoms, signs, or abnormal laboratory test results

To measure the physiologic effect of disease or disorder

To screen individuals at risk of having pulmonary disease

To assess preoperative risk

To assess prognosis

Monitoring

To assess response to therapeutic intervention

To monitor disease progression

To monitor patients for exacerbations of disease and recovery from exacerbations

To monitor people for adverse effects of exposure to injurious agents

To watch for adverse reactions to drugs with known pulmonary toxicity

Disability/impairment evaluations

To assess patients as part of a rehabilitation program

To assess risks as part of an insurance evaluation

To assess individuals for legal reasons

Other

Research and clinical trials

Epidemiological surveys

Derivation of reference equations

Preemployment and lung health monitoring for at-risk occupations

To assess health status before beginning at-risk physical activities

WHEN TO DO AND WHEN NOT TO DO?

Table 1. Indications for Spirometry

D	iag	no	s	s
	_			

- To evaluate symptoms, signs, or abnormal laboratory test results To measure the physiologic effect of disease or disorder To screen individuals at risk of having pulmonary disease
- To assess preoperative risk
- To assess prognosis

Monitoring

- To assess response to therapeutic intervention
- To monitor disease progression
- To monitor patients for exacerbations of disease and recovery from exacerbations
- To monitor people for adverse effects of exposure to injurious agents
- To watch for adverse reactions to drugs with known pulmonary toxicity

Disability/impairment evaluations

- To assess patients as part of a rehabilitation program
- To assess risks as part of an insurance evaluation
- To assess individuals for legal reasons

Other

- Research and clinical trials
- Epidemiological surveys
- Derivation of reference equations
- Preemployment and lung health monitoring for at-risk occupations
- To assess health status before beginning at-risk physical activities

Table 2. Relative Contraindications for Spirometry

Due to increases in myocardial demand or changes in blood pressure Acute myocardial infarction within 1 wk Systemic hypotension or severe hypertension Significant atrial/ventricular arrhythmia Noncompensated heart failure Uncontrolled pulmonary hypertension Acute cor pulmonale Clinically unstable pulmonary embolism History of syncope related to forced expiration/cough

- Due to increases in intracranial/intraocular pressure Cerebral aneurysm Brain surgery within 4 wk Recent concussion with continuing symptoms Eye surgery within 1 wk
- Due to increases in sinus and middle ear pressures Sinus surgery or middle ear surgery or infection within 1 wk
- Due to increases in intrathoracic and intraabdominal pressure Presence of pneumothorax Thoracic surgery within 4 wk Abdominal surgery within 4 wk Late-term pregnancy

Infection control issues

Active or suspected transmissible respiratory or systemic infection, including tuberculosis Physical conditions predisposing to transmission of infections, such as hemoptysis, significant secretions, or oral lesions or oral bleeding Due to increases in myocardial demand or changes in blood pressure Acute myocardial infarction within 1 wk Systemic hypotension or severe hypertension Significant atrial/ventricular arrhythmia Noncompensated heart failure Uncontrolled pulmonary hypertension Acute cor pulmonale Clinically unstable pulmonary embolism History of syncope related to forced expiration/cough

Due to increases in intracranial/intraocular pressure Cerebral aneurysm Brain surgery within 4 wk Recent concussion with continuing symptoms Eye surgery within 1 wk

Due to increases in sinus and middle ear pressures Sinus surgery or middle ear surgery or infection within 1 wk

Due to increases in intrathoracic and intraabdominal pressure Presence of pneumothorax Thoracic surgery within 4 wk Abdominal surgery within 4 wk Late-term pregnancy

Infection control issues

Active or suspected transmissible respiratory or systemic infection, including tuberculosis Physical conditions predisposing to transmission of infections, such as hemoptysis, significant secretions, or oral lesions or oral bleeding

ACTIVITIES TO AVOID BEFORE A SPIROMETRY APPOINTMENT

- Smoking and/or vaping and/or water pipe use within 1 h before testing (to avoid acute bronchoconstriction due to smoke inhalation)
- Consuming intoxicants within 8 h before testing (to avoid problems in coordination, comprehension, and physical ability)
- Performing vigorous exercise within 1 h before testing (to avoid potential exercise-induced bronchoconstriction)
- Wearing clothing that substantially restricts full chest and abdominal expansion (to avoid external restrictions on lung function)

WHEN TO STOP BRONCHODILATORS?

Bronchodilator Medication	Withholding Time
SABA (e.g., albuterol or salbutamol)	4–6 h
SAMA (e.g., ipratropium bromide)	12 h
LABA (e.g., formoterol or salmeterol)	24 h
Ultra-LABA (e.g., indacaterol, vilanterol, or olodaterol)	36 h
LAMA (e.g., tiotropium, umeclidinium, aclidinium, or glycopyrronium)	36–48 h





- **FVC:** maximal volume of air exhaled with **forced effort** from a maximal inspiration
- **FEV1:** maximal volume exhaled in the first second of a forced expiration from a position of full inspiration
- **FEV6:** when a subject doesn't fully exhale, the volume measured over 6 seconds can be used as an approximate estimate of forced vital capacity (FVC)
- **PEF:** maximum expiratory flow achieved from a maximum forced expiration
- **Lower limit of normal:** < 5 percentile for a gender, height, weight and BTPS

NORMAL SPIROMETRIC DIAGRAM

- A= FLOW-VOLUME LOOP
- B= VOLUME-TIME CURVE



WITHIN MANOEUVRE EVALUATION

ACCEPTABLE vs **USABLE**

Do not meet all of the criteria, but may be the best that the patient is able to do on that occasion, and although the FEV1 and/or FVC measurements are not technically acceptable, they may be clinically useful

ACCEPTABILITY CRITERIA:

- $_{\odot}$ BEV <5% of FVC or 100 mL, whichever is greater
- Hesitation time less than 2 sec
- EOFE standards
- \circ No cough in the 1st second
- No glottic closure
- No evidence of leak or obstructed mouthpiece
- If the maximal inspiration after EOFE is greater than FVC, then FIVC-FVC must be <100 mL or 5% of FVC, whichever is greater

Table 7. Summary of Acceptability, Usability, and Repeatability Criteria for FEV₁ and FVC

	Required for	Acceptability	Required for	or Usability
Acceptability and Usability Criterion	FEV ₁	FVC	FEV ₁	FVC
Must have BEV \leq 5% of FVC or 0.100 L, whichever is greater Must have no evidence of a faulty zero-flow setting Must have no cough in the first second of expiration* Must have no glottic closure in the first second of expiration Must have no glottic closure after 1 s of expiration Must achieve one of these three EOFE indicators: 1. Expiratory plateau (\leq 0.025 L in the last 1 s of expiration) 2. Expiratory time \geq 15 s 3. FVC is within the repeatability tolerance of or is greater than	Yes Yes Yes No No	Yes Yes Yes Yes Yes	Yes Yes Yes No No	Yes Yes No No
the largest prior observed FVC ^T Must have no evidence of obstructed mouthpiece or spirometer Must have no evidence of a leak If the maximal inspiration after EOFE is greater than FVC, then FIVC – FVC must be ≤0.100 L or 5% of FVC, whichever is greater [‡]	Yes Yes Yes	Yes Yes Yes	No No No	No No No

Repeatability criteria (applied to acceptable FVC and FEV₁ values)

Age >6 yr: The difference between the two largest FVC values must be ≤0.150 L, and the difference between the two largest FEV₁ values must be ≤0.150 L

Age ≤6 yr: The difference between the two largest FVC values must be ≤0.100 L or 10% of the highest value, whichever is greater, and the difference between the two largest FEV₁ values must be ≤0.100 L or 10% of the highest value, whichever is greater



Figure 1. Back-extrapolated volume (BEV). Time 0 is found by drawing a line with a slope equal to peak flow through the point of peak flow (red line) on the volume–time curve and setting Time 0 to the point where this line intersects the time axis. The BEV is equal to the volume of gas exhaled before Time 0 (inset), which, in these two examples from the same patient, is 0.136 L for the left panel (acceptable) and 0.248 L for the right panel (unacceptable). For this patient, the BEV limit is 5% FVC = 0.225 L.

BACK-EXTRAPOLATED VOLUME

EOFE CRITERIA



BETWEEN MANOUEVRE EVALUATION

REPEATABILITY CRITERIA

Age >6 yr: the difference between the two largest FVC values must be

<150 ml, and the difference between the two largest FEV1 values must

be <150 ml



Q. A 46 year old lady with history of episodicwheezing and breathlessness for 30 yearspresented with worsening breathlessness.She also gives history of recurrent sneezingand nasal discharge. Examination revealsdiffuse wheeze. A spirometry was performed.Interpret the same.



• ACCEPTABLE, >15 S

OBSTRUCTIVE PATTERN

FEV1- LOW

FVC- NORMAL

FEV1/FVC- LOW

"SCOOPED OUT"/"STEEPLE SIGN"

D/D OF OBSTRUCTIVE PATTERN

- BRONCHIAL ASTHMA
- o COPD
- BRONCHIECTASIS
- BRONCHIOLITIS
- CYSTIC FIBROSIS

Bronchodilator Responsiveness

• Bronchodilator administration –

Salbutamol (4 puff =400 mcg) – spirometry after 15 min Ipratropium bromide (160 mcg)- spirometry after 30-45 min

• Bronchodilator responsiveness- Post B.D. FEV1 – Pre B.D. FEV1 X 100 Predicted FEV1 (acc. to GLI)

Increase 10 % in FEV1 or FVC (ERS/ATS Technical Standard Committee)

Increase 12% and 200 ml in FEV1 or FVC (GINA 2024)- For diagnosis of Asthma

Z-SCORE

2005 ATS/ERS statement

2021 ATS/ERS technical standard

 Severity of lung function impairment
 • Using FEV1 (includes obstruction or restriction):
 • For all measures use z-score: Mild: FEV1 >70% predicted

 Mild: FEV1 >70% predicted
 Mild: -1.65 to -2.5

 Moderate: 60–69% predicted
 Moderate: -2.51 to -4.0

 Moderate-to-severe: 50–59% predicted
 Severe: <-4.1</td>

 Severe: 35–49% predicted
 Very severe: <35% predicted</td>

 Q. A 62 year old gentleman presented with progressive dyspnoea and dry cough for 1 year. You note clubbing and velcro crackles on examination. A spirometry was done, interpret the same.



ANSWER- RESTRICTIVE PATTERN

- ACCEPTABLE, PLATEAU REACHED
- DECREASED FVC WITH MINIATURE F-V LOOP

- FEV1- Low, FVC- Low, FEV1/FVC-Normal
- \circ Need TLC < LLN to confirm

Pulmonary

- Fibrosing lung diseases/ Fibrothorax
- Pneumoconioses
- Pulmonary edema
- Parenchymal lung tumors
- Lobectomy or pneumonectomy

Extrapulmonary

- Thoracic cage deformity
- o Obesity
- Pregnancy
- Neuromuscular disorders

Q. A 45 year old patient with longstanding history of smoking presented with productive cough and shortness of breath for 2 years. A spirometry was performed. Interpret the same.

GLOTTIC CLOSURE

NOT ACCEPTABLE



Q. A 6 year old boy presented with history of recurrent hospitalization for shortness of breath. A spirometry was performed. Interpret.

CHILDREN HAVE HIGH ELASTIC RECOIL, HENCE ACCEPTABLE

FEV0.75/FEV0.5 USED

NORMAL SPIROMETRY



FEF₂₅₋₇₅

- Small airway has a large surface area so contribute to resistance at smaller lung volumes
- FEF 25-75 is average flow between between 25% and 75% of exhaled FVC
- This index is taken from the blow with the largest sum of FEV1 and FVC
- Non specific, poorly reproducible and highly variable

Upper Airway Obstruction

Upper Airway Obstruction

- Bronchoprovocation challenge used to assess the airway hyperresponsiveness to a variety of stimuli, such as methacholine, mannitol, and exercise
- Supine and sitting spirometry to evaluate respiratory muscle weakness
- Diaphragmatic weakness is suggested by a decrease in the supine vital capacity (VC) >10%
- Unilateral diaphragmatic paralysis- decrease of **15 to 25%**
- Bilateral diaphragmatic paralysis- decrease OF **50%**

ADVERSE EVENTS

SHORTCOMINGS

- Light-headedness
- o Headache
- Facial congestion
- o Syncope
- Transient urinary incontinence

- Does not tell about RV, FRC, TLC
- Low sensitivity for small airway diseases
- Effort dependent
- Difficult for children, elderly, differently abled

OSCILLOMETRY

12. 12

PRINCIPLE: SOUND WAVE TRAVELS AS PRESSURE WAVE

(Always do oscillometry first followed by spirometry)

RESISTANCE

• 80% by central airways and only 20% by small airways (<2 mm diameter) in adults

Location	Normal	COPD
Pharynx-Larynx	0.6	0.6
Airways> 2mm	0.6	0.9
Airways<2mm	0.3	3.5
Total Airway Resistance	1.5	5.0

R20

J. B. West, Respiratory Physiology, 9/e, 2012

REACTANCE (X)

Inertance in the large, central airways
 Elastic properties of lung tissue (capacitance)

• Reactance is more frequency-dependent than resistance

Reactance (X)= Capacitance + Inertance

In either fibrosis, emphysema or small airway disease, the reactance at lower frequencies would change in the same direction, i.e., become even more negative

AREA OF REACTANCE (AX) AND RESONANT FREQUENCY (FRES)

- Area under the curve between the reactance values for 5Hz and the resonance frequency
- It includes the total area dominated by the capacitance and reflects the elastic properties of the lung
- Increases in any disease of lung periphery

- Resonant frequency (Fres) is defined as the frequency at which the inertial properties of the airway and the capacitance of the lung periphery are equal
- ⁴¹• The frequency at which total reactance is zero

AX: <u>Reactance Area:</u> (< Fres)

In both obstructive and restrictive lung diseases, *fres* is increased above normal

PARAMETERS

- R5 Total respiratory resistance
- R20 Large airway resistance
- R5 R20 Small airway resistance
- X5 Small airway obstruction, Lung elastance and stiffness, Lung heterogeneity
- Fres Airflow obstruction, Lung restriction
- AX What is happening in the distal portion of the lungs, both small airways and lung parenchyma
- X5 inspiratory more than X5e restrictive
- X5 expiration more than X5i obstructive
- o Delta X5

CENTRAL VS PERIPHERAL AIRWAY OBSTRUCTION

Parameter	Healthy	Central airway obstruction	Peripheral airway obstruction with alveolar damage
R5	Normal	> 150 % predicted	> 150 % predicted
R20	Normal	> 150 % predicted	Normal
R5-R20	Close to zero	Close to zero	Increased
X5	Normal	Normal	Increased
AX	Normal	Normal	Increased
Resonant frequency	7-12 Hz	Normal	Increased

ADVANTAGES

- Anyone who can breathe can do oscillometry- children, old age, mentally and physically challenged
- Clinically obstructive airway disease with normal spirometry
- To determine level of obstruction (large airways vs small airways) Role of ultra-fine particle inhaler therapy
- Lung transplant rejection earlier than spirometry

LIMITATIONS

- A newer less standardized methodology
- Limited reference standard values and high intra-subject variability
- Cost

LUNG VOLUME MEASUREMENTS

INDICATIONS

- Determination of lung volumes measurement of FRC with TLC and RV– add to information from spirometry
- A reduced FVC on spirometry may be- restrictive ventilatory defect, air trapping, or the combined obstructive and restrictive defects
- A reduced TLC establishes the presence of a restrictive ventilatory defect
- May enhance the assessment of obstructive ventilatory defects through the detection of air trapping and hyperinflation
- Can be measured using a variety of techniques: body plethysmography, MBW and inert gas dilution, radiographic techniques

HELIUM DILUTION TECHNIQUE

• Closed circuit method based on equilibrium of gas in the lung with a known volume of gas containing a known amount (or fraction) of Helium

PRINCIPLE

- •A spirometer of known volume (V) contains 9–12% helium (He) in air.
- •The patient breathes normally through a mouthpiece (with a nose clip) to get used to the system
- •At the end of a normal tidal breath, a valve opens, and the patient begins breathing the helium mixture.
- •The unknown lung volume (FRC) dilutes the helium, resulting in a new, lower helium concentration

•Equation-

$$FRC = rac{(C1 imes V1) - (C2 imes V1)}{C2}$$

where C1 = initial helium concentration, C2 = final concentration, and V1 = known spirometer volume

- After FRC measurement, the patient performs three vital capacity (VC) maneuvers to calculate TLC and RV
- In obstructive diseases (e.g., COPD, emphysema), equilibration takes longer due to poor gas mixing, and FRC may be underestimated due to air trapping

MULTIPLE BREATH WASHOUT METHOD

- Based on washing out an inert tracer gas from the lungs over multiple tidal breaths.
 - Endogenous gas(N2): Washed out by breathing 100% O2

.

- Exogenous gas (Sulfur hexafluoride): Washed out using room air
- The difference between the initial alveolar tracer gas concentration and the amount of tracer gas washed out is used to calculate FRC

• MEASUREMENT TECHNIQUE

- 1. The patient breathes tidally to establish a stable end-expiratory lung volume (~30–60 sec).
- 2. The patient first breathes room air (pre-washout) \rightarrow then switched to 100% $O_2 \rightarrow N_2$ is gradually washed out.
- 3. Tracer gas concentration is continuously monitored
- 4. The washout ends when end-tidal tracer gas concentration <1/40th of the starting concentration for 3 consecutive tidal breaths
- 5. After FRC is determined, the patient performs linked maneuvers to calculate TLC and RV
- 6. Waiting period of 2× the washout time between maneuvers (longer for severe obstruction)

FIGURE 5 Display of the time course of nitrogen (N₂) (%) and flow ($L \cdot s^{-1}$) throughout the standard multiple breath washout measurement with the patient breathing 100% oxygen. When expressed as N₂% versus volume instead of time (not shown), the area under the curve would be the N₂ volume washed out.

LUNG CLEARANCE INDEX (LCI)

- A measure of ventilation efficiency obtained from MBW testing
- Reflects how evenly gas is distributed and cleared from the lungs
- Particularly useful in detecting early small airway disease, even before spirometry shows abnormalities
- Normal LCI values range from 6–7 in healthy individuals
- A higher LCI means that more breaths (or volume) are needed to wash out the lungs, indicating ventilation inhomogeneity, suggesting airway obstruction or small airway disease
- LCI is more sensitive than spirometry in detecting early lung disease, especially in Asthma, COPD, CF, BPD

BODY PLETHYSMOGRAPHY

PRINCIPLE:

- Changes in alveolar pressure(PA) may be inferred from changes in plethysmograph pressure.
- A shutter mechanism is placed close to the mouth following which voluntary respiratory efforts are performed against closed shutter.
- The change in PA is estimated by recording the change in mouth pressure.
- ΔPA is plotted against simultaneous plethysmographic pressure changes during respiratory effort against a closed shutter to measure absolute intrathoracic gas volume
- Based on Boyle's law (P1V1=P2V2)

TABLE 1 Advantages and disadvantages of lung vo	lume measurement techniques	
	Advantages	Disadvantages
Body plethysmography: measures volume of all compressible gas	Shorter testing period Measures all thoracic gas Requires only short time to repeat measurements	Technically challenging to administer and perform Potential for claustrophobia Can overestimate FRC in severe obstruction Higher equipment cost and space requirements Cabin may not accommodate patient's weight or size
Multiple breath washout: measures volume of gas in ventilated areas	Quiet breathing technique for measurement of FRC	Requires slightly larger tidal volumes Longer testing period Requires more time to repeat measurements Can underestimate FRC in obstructive lung disease Potential risk to patients with ventilation sensitive to high level of inspired oxygen
Helium dilution: measures volume of gas in ventilated areas	Quiet breathing technique for measurement of FRC	Longer testing period Requires CO ₂ absorber, desiccant and O ₂ bleed-in Requires more time to repeat measurements Can underestimate FRC in obstructive lung disease

FRC: functional residual capacity; CO₂: carbon dioxide; O₂: oxygen.

MAXIMAL RESPIRATORY PRESSURES

- Indicated whenever there is an unexplained decrease in vital capacity or respiratory muscle weakness is suspected clinically
- Maximal inspiratory pressure (MIP), measured near RV, is the maximal pressure that can be produced by the patient trying to inhale through a blocked mouthpiece after a full exhalation
- Maximal expiratory pressure (MEP) is the maximal pressure measured during forced expiration through a blocked mouthpiece after a nearly full inhalation to TLC
- Average MIP and MEP for adult men are -100 and +170 cm H2O, respectively, while the corresponding values for adult women are approximately -70 and +110 cm H2O, respectively

DLCO/TRANSFER FACTOR

- The DLCO measures the ability of the lungs to transfer gas from inhaled air to the red blood cells in pulmonary capillaries
- Misnomer- usually obtained at rest when the index is submaximal so it is not a capacity measurement + Several processes contribute to the rate constant, not only diffusion
- CO has a high Haldane constant, binds with Hb 200-300 times more avidly than O2
- Reverse reaction being extremely slow, practically no back pressure/tension

PREPARATION

- No cigarette smoking on the day of the test
- No use of inhaled bronchodilators on the day of the test

• No supplemental oxygen for at least 15 minutes prior to and during the test (Use of supplemental oxygen can decrease DLCO by 0.35 %/mmHg change)

DLCO MANOUEVRE

- 3 to 4 normal breaths
- Followed by full inspiration, full expiration and than full inspiration and hold for 10 sec ± 2 , followed by forceful exhalation
- Gas: 0.3% CO, 0 to 14% helium, 21% O2, rest N2

WHAT AFFECTS DLCO

- Thickening of the alveolar-capillary membrane
- Loss of alveolar membrane surface area
- Reduction in volume of RBC in pulmonary capillaries
- o Altitude
- Lung volume
- Carboxyhemoglobin levels

DLCO=KCO×VA KCO = transfer co-efficient VA =Alveolar volume → no. of contributing alveoli

6-MINUTE WALK TEST

- Objective evaluation of submaximal functional exercise capacity
- Simple to perform, better tolerated, more reflective of activities of daily living and requires no advance training to technicians
- Assesses global & integrated response of all systems (pulmonary, cardiovascular, systemic & peripheral circulation, blood, neuromuscular & muscle metabolism)

INDICATIONS

- Pre & post treatment comparisons
- 1. Lung transplantation
- 2. Lung resection
- 3. Lung volume reduction surgery
- 4. ILD
- 5. Pulmonary rehabilitation
- 6. COPD
- 7. Pulmonary hypertension
- 8. Heart failure

- Functional status
- 1. ILD
- 2. COPD
- 3. Heart failure
- 4. Peripheral vascular disease
- 5. Fibromyalgia
- Mortality prediction
- 1. Heart failure
- 2. COPD
- 3. Primary pulmonary hypertension

PRE-REQUISITES & PRECAUTIONS

- Long, flat, straight , enclosed corridor
- o 🛛 30 m walking course, length marked every 3 m 🖡
- Turn around points marked with cone

- Line denoting starting and ending of 60 m lap marked with bright tape
- Rapid and appropriate response to emergency facility in place
- Oxygen, sublingual nitroglycerin, aspirin & inhalers etc must be available
- Technician should be certified in BLS
- In those on chronic oxygen therapy, oxygen should be given at their standard rate

HOW DO WE PERFORM THE TEST?

- Ask the patient rate their dyspnea & fatigue using Borg scale
- Set lap counter to 0 & timer to 6 minutes
- Instruct the patient to walk at own pace in 6 minutes. Patient can slow, stop, rest and resume again
- Start the timer when the patient starts to walk and click lap every time the patient reaches the starting line
- When the test is done, grade the dyspnea & fatigue with Borg scale again
- If pulse oximetry used, measure SpO2 & pulse rate

The modified Borg Scale for assessing the intensity of dyspnea or fatigue

0	Nothing at all
0.5	Very, very slight (just noticeable)
1	Very slight
2	Slight (light)
3	Moderate
4	Somewhat severe
5	Severe (heavy)
6	
7	Very severe
8	
9	
10	Very, very severe (maximal)

INTERPRETATION OF SCORES:

- Primary outcome is the distance covered in meters over 6 mins
- Normal norms: healthy adult has a reported range from 400 to 700m
- Age and sex specific reference standards are available for final interpretation
- A lower score reflecting less distance covered in 6 min indicates worse prognosis

WAKE UP... AND INTERPRET THESE REPORTS

Postgraduato Medical Edu. & Research, Chandigarh

10

				_			10			-	Mye.	0.5		
Sex at Birth Fernalio Ethnicity South-East Asian			Height		153	cm			Asthma	í.				
		ksian.		Weight	ŧ	45	kg	BMI 19	19.2 COPD				+	
FVL (ex/in))						Ye	ur FE	/1 / Po	edicte	d: 66%	é		
Post Time	07-4	02-2025	10:51:56		Interpr	etation	60	LD(200m	Hanlie		RTPS	NAEVO		1/1/02
rsitt time	07-02-2025 11:27:02		11:27:02		Predict	led	O	habra (Inc	fia), 2014	1.00	wira (i	ny chi		2/1002
Parameter	Best	LLN	Spred	Drad	Total 2	1000		Post						
Time			-		10:54:22	10-55-44	Trial 1	Best	SPred	Chg	SChg	Trial 3	Trial 2	Trial
FVC (L)	2.11	1.72	94	2.24	2.11	1.99	10.53.10		1000	2.22		11:20:53	11:28:15	11:27:
FEVT JLJ	1.03*	1.08	66	1.55	1.03*	0.92*	1.02*	1.37	108	0.31*	14*	2.41	1.90	1,6
FEF25-35 m.m.	0.488*	0.635		0.718	0.488*	0.460*	0.486*	8.527*	84	0.25*	16*	1.27	1.05*	1.0
PEF IL/mint	6.25*	0.71	22	1.18	0.26*	0.21*	0.24*	0.42*	36	0.040		0.527*	0.552*	0.65
FET IN	15.9	156	42	215	120*	134*	117*	144*	67	30	65	0.42*	0.46*	0.3
PVC and FEV1 C	Jusity Bal	d is Are	antshis .	+	15.7	15.2	14.5	12.8	-	-3.0	- 33	10.0	139*	16
· Indicates valu	e outside r	thermol ex	opratile, i	Normal a	n Usable,	Strikethn	ough is N	ot-Usable		0.55	0.55	NCB.	13.0	12
Session Quality	E	Pre	inge or si	prificant 714	post cha	nge.								
		Pos		11VI - A.	PVC - B (PVC Var=(0.110. (5.41	E FEVT V	er-0.001.0	0.2%()				
System Interpret	station.	Pre	01 - J ^a		AC-E(P	AC Alt=0	51L (21.1	AL FEVI V	ar=0.20L	15.5%()				
		p												
Overall Syst, In	litpret.													
Pre-post %char	iges for FE	VI, FVC a	we calcula	ted acco	rdine to a	the first of	-	117993						
Pre					and all	one though	15 2022 1	ectinical s	tandard.					
IVC EST	and the second		tra pre	Gitted		Pp	ut							
FEV1	1000	14		-			IVC E	1	1	un p	renticted			
FEV1/FVC EN	ALL PROPERTY.			-			FEV1 E	And Address	-			1 1		
FEF25-75	*	1		-		. FE	V1/EVC			1	-			
P07 [the second s		the second se	-		1 11	202.34.0		-	-	-			
	the second se				_		173-13	COLUMN AND ADDRESS	1 1 1 1		_	_	-	
1 score 5		*	1	-		3	PEFE		*		-	1 1		
1 score 5	4	*	4	0	- I	Ξ,	PEF		*	H		H		
2 scure 5	4	- <u>* </u>	4	0	2	1	PEF F	-		-	0		=	
1 score 5	4	1 2	1		1	1,	PEF F	4		1	0			
6	4 4	- NT	1	0 Perform		1.	PEF F	4		1	0			
5 score 5		- #[2	1 1111	0 Pre Takit Pre Takit Pre Takit Pre Takit	2		PEF F	4			0		- 111	
1 score 5	1	- N [1	D Perfact Perfact Perfact Perfact Perfact		1,	PEF E	4		1	0		- 1111	
6	1		1 11111	C Pre Takis Pre Takis Pre Takis Pre Takis Pre Takis Pre Takis	2	1,	PEF E	4		1	0		- 111	
1 soure 5	1 1			0 Partial Partial Partial Partial Partial	2	1,	PEF F	4		1	0			
1 some 5	1.2			0 Per Taul 2 Per Taul 4 Per Taul 4 Per Taul 1 Per Taul 1 Per Taul 1 Per Taul 1	2	17.	PEF	4		1	0	1 2		
1 same 5	1.1			0 Per Takit Per Takit Per Takit Per Takit Per Takit Per Takit		17.	PU F	4	4 4		0	1 2	- 111	
1 mm 5	1.2			0 Per Tails Per Tails Per Tails Per Tails Per Tails Per Tails			PU F	4	1		0	1 2	100-	
1 sourt 5				0 Per Yali Per Yali Per Yali Per Yali Per Yali Per Yali			PO F	4	1		0	1 2		
1 score 5	CT:			D Per Yaki Per Yaki Per Yaki Per Yaki Per Yaki Per Yaki			PEF F	4			0	1 2		
Liscore 5	CTT I		Û.	D Pro Yauki Pro Takis Pro Takis Pro Takis Pro Takis			PEF F	4	1		o	1 2		
2	1. 1. I. M.			0 Per Yada Per Yada Per Yada Per Yada Per Yada Per Yada			PO F	4	-1 -1		o	1 2		
1 2 2	1. 1. 1.		0	0 Per Yada Per Yada Per Yada Per Yada Per Yada Per Yada	2		PO F	4	-1 -1		0	1 2		
1 2009 1 6 4 2 2 3 4	1.1.2.20			0 Per Yaki Per Yaki Per Yaki Per Yaki Per Yaki	2		PEF E	4	1 1		0	1 2		
2	W. L.L.		Ŭ.	0 Per Yaki Per Yaki Per Yaki Per Yaki Per Yaki			PO F	4	1 1		0	1 2		
2	1.1.1		i i i i i i i i i i i i i i i i i i i	0 Per Takin Per Takin Per Takin Per Takin Per Takin Per Takin			PO E	4	4 4		0	1 2		
1 2 2	1. 1. J. J.			0 Per Taria Per	2		PO E	4			0			
2	1. 1. L. W		Ĵ.	0 Pro Yang Pro Tang Pro Tang P			PO E	4			0	1 2		
2	· · · · · · · · ·			0 Per Yacz Per Tale Per Tale Per Tale Per Yacz Per Yacz Per Yacz			PO D	4			0			
2	· · · · ·			0 Pro Yang Pro Talar Pro Talar Pro Talar Pro Talar			POT E		3 1		0			
1 2 2	·		Ĵ.	0 Per Yacji Per Tali Per Tali Per Yacji Per Yacji Per Yacji			POP E	4			0			1144
2				0 Per Yact Per Tale Per Tale Per Yact Per Yact Per Yact			PO E	4			0			
2	· · · · · · · · · · · · · · · · · · ·			9 Per Taut Per Taut Per Taut Per Taut Per Taut			POP In the second	4			0			
2 2				g The Young of The			POT	4			0			
2				9 Pro Tues Pro Tues P			POP In the second	4			0			
2 court 5	· · · · · ·			0 Pro Yest Pro Table Pro T			POP In the second	4			0			
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2				g The Yest Table Prov Table Prove Table Pr			POT D	4			0			
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2				g The Yest Test			Per p				0			
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	· ····································				5		POT E				0			

Department of Pulmonary Medicine Postgraduate Medical Edu. & Research, Chandigarh

							ID			_	Age:	27	_		_		
ex at Birth	Femal	le Fast A	sian		Height Weight		155 38	cim eg	BMI 15.	8	Asthm COPD						
theacity	3000	South-Cast Poster		Yo					ur FE	/1 / Pre	dicted	d: 32%				_	
FVL (ex/in)			-		X. x 1002	-	60	0/2008	Alartie		BTPS (N/EX)	1.12	2/1.02			
Test Date Post Time	05-02-2025 10:11:13 05-02-2025 10:32:09				05-02-2025 10:11:13 Interpretation 05-02-2025 10:32:09 Predicted				Chi	ualaria (Inc	Sa), 2014 •	1.00	Dis back				
	Pre						Post		-			Tabl 2	Trial 3				
Parameter	Best	LLN	%Pred	Pred	Trial 2	Trial 4	Trial 3	Best	%Pred	Chg	%Chg	1/1011	10012	10-14-23			
Time	1.	0.319			10:12:33	10:14:06	10:13:19		-1227	12022		10:34:50	1 141	1 124			
EVC ILT	1.07*	2.18	40	2,70	1.06*	1.07*	1.05*	1.17*	43	0.09		1.17	1.14	0.01*			
FEV1 ILI	0.76*	1.86	32	2.33	0,76*	0.73*	0.71*	0.87*	37	0.11	5	0.87*	0.84*	0.01			
FEV1/FVC	0.704*	0,768		0.852	0.710*	0.680*	0.672*	0.741*		0.038	4	0.741*	0.736*	0.727-			
FEF25-75 [L/s]	0.52*	1.69	19	2.81	0.52*	0.46*	0.42*	0.64*	23	0.12	23	0.64*	0.62*	0.60-			
PEF (L/min)	103*	243	31	336	96*	102*	103*	130*	39	27		130*	124*	99*			
FET isl	8.4	100			6.5	8.4	7.9	7.9		-0,5	-	7.9	8.3	8.4			
FVC and FEV1 C	Juality: Bol	Id Is Ace	ceptable,	Normal i	is Usable,	Strikethn	ough is N	ot Usable									
* indicates valu	e outside r	normal ra	ange or sk	anificant	post char	nge.											
Seisine Quality		Pre		EVI-A.	FVC - A I	FVC Varel	0.011 (0.91	ik FEVI V	ar=0.031.0	3.4%))							
activity denied		Pos		EV1 - A.	FVC - A (FVC Variel	0.03L (2.2	ST FEVI	/ar=0.02L	(2.9%))							
Sustain Internet	tation	Pre	3			0 - A A - 1 - 0											
System manyou	decised.	Pos															
Pre-post %chan	ges for FEN	VI, FVC a	re calcula	ted acco	rding to I	the ERS/A	TS 2022 t	echnical s	standard,	1935		8					
Pre		н	N pre	dicted		Po	st nuc P		_	LUN I	predicted						
FV0R	and strength in					-	TUC B		-	++	=		_				
EDV1 (DV7 EBU		-				= 10	HUDAC I		1 4	-							
FFF25.75						- 11	F25-75 E		*1	1	-	T					
PEF MIL	*	and an in	01-			-	PEF F	* 1.	1		_	1					
z-score-5	-1 -3	-2	-1	0 1	2	3	z-score-5	-4	a .	2 .1	0	1 2	3				
6.0000.00) 	347571 173		2344	St. 1 Hereit	1021 - 10		300010										
14- 1	L L J	1.11	1 3	Pre Trief 2	4	- T	: 1.3	11	ool 14	1.1		1.1	- T. 1	Tree .			
12-			-	Pos Trial 3										1.1			
10		-	+	Post Trei 1	3			-		_			-	-			
10 I S			1	Post Trail 2	1		1					0					
				Predicted.	Ξ		10							1.1			
e	1	11		0.00	Ĕ Z		1 -					_	-	-			
4	1			_	Volt		11										
	101	11			0.00		1	leader.	and the second	_							
Z 2 B	1 .01			-		1				and interests							
= 0	11		-			19	-					: F.		1.1.3			
S N	M		1.1	+	0	1								1.11	-		
	4	1.1.		1	-0	0.5 0	1	2	3	4	5	6	7	8			
4	++		++-	-						Time	[8]						
	1-1-	1. 10	1.1-	1													
	1	111		1													
	1																
4	11		11														
-6	11																
-8 -10			H	-													
-6 -8 -10 12		1															
-6																	

24.5

Department of Pulmonary Medicine Postgraduate Medical Edu. & Research, Chandigarh

			ID	ID: .			Age: 25								
-		Temple Height		162	5 cm			Asthm	a						
Sex at Birth	Fema	ile	40.00		Height		611		BMI 26	2	COPD		-		
Ethnicity	South	h-East As	han		weight			19							
FVL (ex/in)			Your FEV1				/1 / Pr	edicte	icted: 118%						
Test Date	12-0	2-2025 1	0:16:07		Interpr	etation	GO	LD(2008)	/Hardie		BTPS ((N/EX)	1.1	2/1,04	
Post Time	12-02-2025 10:52:56		0:52:56		Predict	ed	Chi	sabra (Im	dia), 2014	• 1.00					
	12162							Post							
-	Pre		w. Dec. d	Read	Trial 3	Telal 2	Trial 4	Best	%Pred	Chg	%Chg	Trial 4	Trial 3	Trial 1	
Parameter	Best	LUN	WPred	evied	10-10-57	10-18-15	10-20-34			0.000		10:55:59	10:55:22	10:53:36	
Time				2.02	3 45	3 46	3.44	3.43	131	-0.03	-1	3.43	3.43	3.38	
FVC [L]	3.46	2.50	134	2.02	3.30	3.68	2 59	2.97	129	0.27*	12*	2.97	2.96	2.92	
FEVT [L]	2.70	1.82	118	2.29	2.70	2.03	6.33			0.085		0.865	0.863	0.862	
FEV1/FVC	0.779	0.754		0.835	0.781	0.776	0.754	0.064		0.003	40	3.20	3.10	3.21	
FEF25-75 (L/s)	2.36	1.72	82	2,86	2,36	2,33	Z.13	3.29	115	0.93	40	3.6.7	220	371	
PEF (L/min)	322	232	100	321	322	315	293	339	105	17		339	330	70	
FET (s)	9.0	10.52		1.1	9.4	9.0	9.6	7.5		-1.5		7.6	15	1.3	
FVC and FEV1 C	Juality: Bo	id is Acc	eptable,	Normal	is Usable,	Strikethn	ough is N	ot Usable	53 - E						
• Indicates value	e notride	normal ra	ange or si	gnificant	post cha	nge.									
Service Custin		Pro		FEVI - A	FVC - A O	FVC Varal	0.011 (0.21	6): FEVI V	/ar=0.01L	0.5%))					
Session Quanty		Res		EEVI - A	FVC - A C	FVC Varal	0.00L (0.11	ET: FEVT V	/ar=0.00L	(0.2%))					
Cators Interes	and an	Pro-	3 =0												
system enterpri	etation	Pre													
		POS													
Overall Syst. Int	lerpret.					-	TE 2022 .	arbeiral.	bachast						
Pre-post %chan	iges for FE	VI, FVC 4	re calcula	sted acce	requiring to	the LRG/A	15 2022 1	econocar	stantianta.						
Pre		11	N or	dicted		Po	et :			LIN	predicted	1			
FVC	1-1-1	T		1		*	FVC E	CO.				1	*		
FEV1	St 1	1		-	1 * 1		FEVT E	1000	-		_	1	*		
FEV1/FVC	11 mar 17	1000 C	*	-		1 11	V1/FVC	1000 H	ART SHOWS		*				
FEF25-75			1*		I I	F	F25-75		1	1 1	1	RT.			
PEF	0.000	1	1	+			PEF D	of the Law			*				
2 score 5	4 3	2	-1	0	1 2	3	z-score-5	4		2 -1	0	3	2 3		
					S 0.50										
			_	Pre Trail		-									
1000	N		-	Pa Tod2		S 11									
6	in	_	-	Pre Trief 4					-	Charles and				****	
	Part		1	Prest Tried 4			1	and and a							
	1	1		Post Test 1	1		10-								•
4	1	61	•	Pedead	2	17	100								
11	n	110			Ê 2	-	11	-			-				
- 11	1	16	S		공	- 14	15	1010							
2	1	1	14		>	1	11								
- /		10	do		1	-1	11								
ĩ. I.	113	1900	1.48			10	1								
20-11	11	1	11	1		1.									
2 1	~	Since 1		1	0	-	-						-		
NA.			£1	1		0.5 0	1	2	3	4	Time lat			8	
-2	12 mar		11 1	1							cause fel				
1	1.10	N. 1	1 1												
	1-1000	a No	A												
4	11-2	Sel	20												
	1	A.	5.1												
1		0	2												
.8	_	_													
	8	÷	14	- 31											
-1 0		- 11 -													
	valum	n Irl													

DEPARTMENT OF PULMONARY MEDICINE Postgraduate Institute of Medical Education and Research

Chandigarh

Name CR No.	Age: 4	3 Sex	: Male	Date:-27-01-2025	Visit Time	10:56:13
	Height:	159.50	Weight:	53.00	BSA:	1.54
	Pre-Bronch			Post-Bronch		
	Actual	Pred	%Pred	Actual	%Pred	
SPIROMETRY			12.22			
FVC (L)	1.76	3.53	49			
FEVI (L)	1.50	2.96	50			
FEV1/FVC (%)	85	84	101			
PEF (L/min)	407.1					
FEF Max (L/sec)	6.79	8.05	84			
FIVC (L)	1.88	4.12	45			
Expiratory Time (sec)	10.74					
SVC(I)	1.80	3.53	50			
	1.01	2.86	35			
ERV (L)	0.79	0.67	117			
DIFFUSION						
DLCOunc (ml/min/mmHg)	11.45	26.24	43			
DLCOcor (ml/inin/mmHg)	8.847	26.24				
DL/VA (ml/min/mmHg/L)	4.66	5.81	80			
VA(L)	2.46	5.43	45			
IVC (L)	1.76					
BHT (sec)						

. . .

THANK YOU